Mirjam De With

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort study.

Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort study.

Journal: The Lancet regional health. Europe

Published: November 14, 2025

Real-World Impact of UGT1A1 Genotype-Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study.

Real-World Impact of UGT1A1 Genotype-Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: November 05, 2025

Predictors of poor treatment tolerability in older patients receiving fluoropyrimidine-based chemotherapy: A prospective cohort study.

Predictors of poor treatment tolerability in older patients receiving fluoropyrimidine-based chemotherapy: A prospective cohort study.

Journal: Journal of geriatric oncology

Published: October 21, 2025

Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study.

Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 04, 2025

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.

Journal: Clinical pharmacokinetics

Published: June 22, 2023

Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe.

Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe.

Journal: ESMO open

Published: December 05, 2022

Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.

Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: November 23, 2022

Response to "Plasma Uracil as a DPD Phenotyping Test: Pre-analytical Handling Matters".

Response to "Plasma Uracil as a DPD Phenotyping Test: Pre-analytical Handling Matters".

Journal: Clinical pharmacology and therapeutics

Published: October 13, 2022

DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events.

DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events.

Journal: JCO precision oncology

Published: July 21, 2022

Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?

Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 23, 2022

Search for Unstable Sterile Neutrinos with the IceCube Neutrino Observatory.

Search for Unstable Sterile Neutrinos with the IceCube Neutrino Observatory.

Journal: Physical review letters

Published: April 06, 2022

Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.

Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.

Journal: Clinical pharmacology and therapeutics

Published: February 22, 2022

Showing 1-12 of 36

Last Updated: 09/26/2026